巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Novavax

    NVAX
    62.050
    4.900
    8.57%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Novavax - 延遲價格・最後更新於 05/07 6:56
    最高位
    62.550
    最低位
    55.740
    開市價
    --
    前收市價
    57.150
    成交量(千)
    153.67
    成交額(百萬)
    80.37
    買入
    61.910
    賣出
    62.070
    每手股數
    --
    市值(百萬)
    4,848.25
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    277.800 - 34.880
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Novavax
    證券代碼
    NVAX.US
    所屬板塊
    Biotechnology
    公司業務
    Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
    發行量
    76282986
    公司總部
    21 Firstfield Road
    公司網址
    https://www.novavax.com
    公司電郵
    ir@novavax.com
    公司電話
    +1 240 268-2000

    美股異動 | 諾瓦瓦克斯醫藥(NVAX.US)漲超6% 預計今年底前提供奧密克戎BA.4和BA.5疫苗

    格隆匯··精選
    美股異動 | 諾瓦瓦克斯醫藥(NVAX.US)漲超6% 預計今年底前提供奧密克戎BA.4和BA.5疫苗

    美股異動 | 諾瓦瓦克斯醫藥(NVAX.US)漲超6% 預計今年底前提供奧密克戎BA.4和BA.5疫苗

    格隆匯·
    美股異動 | 諾瓦瓦克斯醫藥(NVAX.US)漲超6% 預計今年底前提供奧密克戎BA.4和BA.5疫苗

    諾瓦瓦克斯預計今年底前提供奧密克戎BA.4和BA.5疫苗

    格隆匯·
    諾瓦瓦克斯預計今年底前提供奧密克戎BA.4和BA.5疫苗

    部分美股抗疫概念股走高

    格隆匯·
    部分美股抗疫概念股走高

    部分美股抗疫概念股走高

    格隆匯··精選
    部分美股抗疫概念股走高

    關於

    Novavax(NVAX.US)所屬的行業板塊為Biotechnology。
    Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
    詳細公司背景可參考: https://www.novavax.com